Böni R, Burg G, Doguoglu A, Ilg E C, Schäfer B W, Müller B, Heizmann C W
Department of Dermatology, University of Zurich, Switzerland.
Br J Dermatol. 1997 Jul;137(1):39-43.
The purpose of this study was to evaluate the expression of the Ca(2+)-binding S100 proteins S100A1, S100A2, S100A3, S100A4, S100A6 and S100B in normal skin. These immunohistochemical staining patterns were compared with those in melanocytic lesions. Paraffin-embedded tissue of normal skin adjacent to 26 naevi, 39 primary cutaneous melanomas and 14 cutaneous melanoma metastases was incubated with polyclonal antibodies against the recombinant human S100 proteins (S100A1, S100A2, S100A3, S100A4, S100A6, S100B) using the alkaline phosphatase anti-alkaline phosphatase method. The S100A2 antibody stained the basal layer of the epidermis and hair follicles of normal skin. Four of 39 primary cutaneous melanomas were positive for S100A2, whereas none of the metastases or naevi showed any immunoreactivity. The S100A3 antibody only stained the inner root sheath cuticle of some hair follicles but no melanocytes or melanocytic lesions. Staining of S100A4 was weak and thus omitted to further analysis. S100A6 faintly labelled keratinocytes. Langerhans' cells, melanocytes and sweat glands. S100A6 immunoreaction was found in two of seven junctional naevi, five of seven compound naevi, and all dermal and blue naevi. There was an intense cytoplasmatic reaction for S100A6 in all primary cutaneous melanomas and in nine of 14 (64%) metastases, S100B was positive in melanocytes and Langerhans' cells, all primaries as well as in the metastases, S100A1 protein was not detected on any of the tissue specimens examined. Whereas S100B and S100A6 antibodies are useful markers for malignant melanoma, expression of S100A4 antibody is too low to be used for immunohistochemical staining. S100A1 and S100A3 antibodies are not expressed in melanocytic lesions and S100A2 is only found in selected tumours. The investigated S100 proteins, including S100B and S100A6, are also expressed in selected elements of normal skin. These findings are important for correct interpretation of staining patterns, when S100 antibodies are used as markers for melanoma or other tumours.
本研究的目的是评估钙结合蛋白S100家族中的S100A1、S100A2、S100A3、S100A4、S100A6和S100B在正常皮肤中的表达情况。将这些免疫组化染色模式与黑素细胞性病变中的模式进行比较。采用碱性磷酸酶抗碱性磷酸酶法,用抗重组人S100蛋白(S100A1、S100A2、S100A3、S100A4、S100A6、S100B)的多克隆抗体孵育26个痣、39例原发性皮肤黑色素瘤和14例皮肤黑色素瘤转移灶附近的正常皮肤石蜡包埋组织。S100A2抗体染色正常皮肤的表皮基底层和毛囊。39例原发性皮肤黑色素瘤中有4例S100A2呈阳性,而转移灶和痣均未显示任何免疫反应性。S100A3抗体仅对一些毛囊的内根鞘角质层染色,而不对黑素细胞或黑素细胞性病变染色。S100A4染色较弱,因此未进一步分析。S100A6对角质形成细胞、朗格汉斯细胞、黑素细胞和汗腺呈弱阳性标记。在7例交界痣中的2例、7例复合痣中的5例以及所有真皮痣和蓝痣中均发现S100A6免疫反应。在所有原发性皮肤黑色素瘤和14例转移灶中的9例(64%)中,S100A6有强烈的细胞质反应,S100B在黑素细胞和朗格汉斯细胞、所有原发性肿瘤以及转移灶中均呈阳性,在所检查的任何组织标本上均未检测到S100A1蛋白。虽然S100B和S100A6抗体是恶性黑色素瘤的有用标志物,但S100A4抗体的表达太低,无法用于免疫组化染色。S100A1和S100A3抗体在黑素细胞性病变中不表达,S100A2仅在某些肿瘤中发现。当S100抗体用作黑色素瘤或其他肿瘤的标志物时,所研究的S100蛋白,包括S100B和S100A6,也在正常皮肤的特定成分中表达。这些发现对于正确解释染色模式很重要。